Nuclear Hormone Receptors and Interacting Proteins

Period of Performance: 02/06/1998 - 07/31/1998


Phase 1 SBIR

Recipient Firm

Invitrogen Corporation
Carlsbad, CA 92008
Principal Investigator


DESCRIPTION: This application proposes to use the new Topocloning(TM) technology developed at Invitrogen to incorporate receptor and RIP cDNA sequences into expression vectors to allow expression of these proteins for analysis of their structure and functions. In addition, the recombinant proteins will be utilized to produce antisera to aid in functional studies. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE